Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Lucille P. Markey Cancer Center at University of Kentucky National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00026533 |
RATIONALE: Thalidomide may stop the growth of thyroid cancer by stopping blood flow to the tumor.
PURPOSE: Phase II trial to study the effectiveness thalidomide in treating patients who have thyroid cancer.
Condition | Intervention | Phase |
---|---|---|
Head and Neck Cancer |
Drug: thalidomide |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | Phase II Trial of Thalidomide for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas and Medullary Thyroid Carcinomas |
Study Start Date: | June 2001 |
OBJECTIVES:
OUTLINE: Patients receive oral thalidomide once daily for 2 weeks and then twice daily. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A maximum of 50 patients will be accrued for this study.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Must meet criteria for 1 of the following:
Radiographic evidence of tumor progression, meeting 1 of the following criteria:
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
Other:
United States, Kentucky | |
Albert B. Chandler Medical Center, University of Kentucky | |
Lexington, Kentucky, United States, 40536-0298 |
Study Chair: | Kenneth Ain, MD | Lucille P. Markey Cancer Center at University of Kentucky |
Study ID Numbers: | CDR0000069053, UKMC-IRB-010069 |
Study First Received: | November 9, 2001 |
Last Updated: | July 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00026533 |
Health Authority: | United States: Federal Government |
stage IV papillary thyroid cancer stage IV follicular thyroid cancer thyroid gland medullary carcinoma recurrent thyroid cancer insular thyroid cancer |
Adenocarcinoma, Follicular Carcinoma, Medullary Thalidomide Thyroid Neoplasms Endocrine System Diseases Recurrence Carcinoma |
Thyroid cancer, papillary Head and Neck Neoplasms Thyroid cancer, medullary Endocrinopathy Thyroid Diseases Thyroid cancer, follicular Endocrine Gland Neoplasms |
Anti-Infective Agents Immunologic Factors Antineoplastic Agents Growth Substances Physiological Effects of Drugs Immunosuppressive Agents Angiogenesis Inhibitors Pharmacologic Actions |
Anti-Bacterial Agents Neoplasms Neoplasms by Site Therapeutic Uses Growth Inhibitors Angiogenesis Modulating Agents Leprostatic Agents |